TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9296217

Group type: EXPERIMENTAL
Intervention: Formestane 250 mg
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Formestane 500 mg
Number of subjects: 152
Study: 8507221

Group type: EXPERIMENTAL
Intervention: Leucovorin (2.5-5.0 mg orally, given 24 hours after weekly methotrexate dose)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (given 24 hours after weekly methotrexate dose)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Leucovorin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Leucovorin and Placebo
Number of subjects: 92
Study: 3551829

Group type: EXPERIMENTAL
Intervention: Ceftazidime monotherapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus cephalothin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus vancomycin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Ceftazidime and cephalothin plus vancomycin
Number of subjects: 102
Study: 31813028

Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0
Study: 28843819

Group type: EXPERIMENTAL
Intervention: Rifampicin-based systemic antibiotics (oral rifampicin with clindamycin or trimethoprim/sulfamethoxazole for 7 days plus nasal mupirocin)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Topical treatment with mupirocin only
Number of subjects: 52
Study: 27141840

Group type: EXPERIMENTAL
Intervention: Immediate Intervention (II)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Wait List (WL)
Number of subjects: 94
Study: 25494594

Group type: EXPERIMENTAL
Intervention: Corn peptides (CPs) 4 g/d for 9 weeks
Number of subjects: 161

Group type: COMPARATOR
Intervention: Whey protein (2 g twice daily)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Corn starch placebo (2 g twice daily)
Number of subjects: 161
Study: 22430300

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection (50 U BT into the internal sphincter)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy (LIS)
Number of subjects: 50
Study: 20362857

Group type: EXPERIMENTAL
Intervention: Custom PRK (wavefront-guided custom treatment)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional PRK
Number of subjects: 28
Study: 18384186

Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study: 15714983

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade using LHRH agonist and androgen antagonist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy (including intermittent hormonal therapy)
Number of subjects: 0
Study: 12879653

Group type: EXPERIMENTAL
Intervention: Metformin with gonadotropins
Number of subjects: 172

Group type: COMPARATOR
Intervention: Classic stimulation protocol alone
Number of subjects: 172

Group type: COMPARATOR
Intervention: Intact ovarian function
Number of subjects: 172
Study: 11051123

Group type: EXPERIMENTAL
Intervention: Sulthiame (STM) 5 mg/kg/day
Number of subjects: 66
Study: 9006790

Group type: EXPERIMENTAL
Intervention: Peppermint oil (90 mg) and caraway oil (50 mg) in an enteric coated capsule
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 1587072

Group type: EXPERIMENTAL
Intervention: 60 mg extended-release fenfluramine plus 15 mg phentermine resin
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 3890395

Group type: EXPERIMENTAL
Intervention: Muzolimine (MZ) 20 mg/day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CL) 50 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both MZ and CL
Number of subjects: 26
Study: 29419569

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg every day
Number of subjects: 40
Study: 26689970

Group type: EXPERIMENTAL
Intervention: Emtricitabine and Tenofovir Disoproxil Fumarate (FTC/TDF)
Number of subjects: 4

Group type: COMPARATOR
Intervention: No detectable drug
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4

Group type: COMPARATOR
Intervention: No FTC/TDF
Number of subjects: 4
Study: 23321657

Group type: EXPERIMENTAL
Intervention: Daily vaginal estrogen cream for 2 to 12 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 42
Study: 21406117

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound plus exercise therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo ultrasound plus exercise therapy
Number of subjects: 46
Study: 20081257

Group type: EXPERIMENTAL
Intervention: Preoperative intravenous tramadol (100 mg)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 224
Study: 17915641

Group type: EXPERIMENTAL
Intervention: Nimesulide in tablets
Number of subjects: 0
Study: 15225828

Group type: EXPERIMENTAL
Intervention: BB genotype
Number of subjects: 0

Group type: COMPARATOR
Intervention: bb genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TaqI genotypes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VDR gene polymorphisms defined by ApaI and FokI
Number of subjects: 0
Study: 11574379

Group type: EXPERIMENTAL
Intervention: Electrical stimulation test
Number of subjects: 566

Group type: COMPARATOR
Intervention: No electrical stimulation test (Control)
Number of subjects: 566
Study: 9645715

Group type: EXPERIMENTAL
Intervention: Pre-enucleation radiation
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1003
Study: 7934010

Group type: EXPERIMENTAL
Intervention: Verbal encouragement
Number of subjects: 28

Group type: COMPARATOR
Intervention: No verbal encouragement
Number of subjects: 28
Study: 3122600

Group type: EXPERIMENTAL
Intervention: Naloxone infusion (0.4 mg loading dose followed by 10 micrograms.kg‐1.hr‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Naloxone infusion (0.2 mg loading dose followed by 5 micrograms.kg‐1.hr‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline infusion (20 ml/hr)
Number of subjects: 24
Study: 29307459

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 1164

Group type: COMPARATOR
Intervention: Non-ICD therapy
Number of subjects: 1164
Study: 28006855

Group type: EXPERIMENTAL
Intervention: Bortezomib, melphalan, prednisone (VMP)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Lenalidomide and low-dose dexamethasone (Rd)
Number of subjects: 479
Study: 26223257

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg + ASA 100 mg
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg + ASA 100 mg
Number of subjects: 213

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 213

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 213
Study: 24117909

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 74
Study: 21173036

Group type: COMPARATOR
Intervention: Heparin-coated CPB (HC-group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Non-coated CPB (NC-group)
Number of subjects: 24
Study: 18469249

Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (M-day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity physical activity (V-day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control day (C-day)
Number of subjects: 11
Study: 20939854

Group type: EXPERIMENTAL
Intervention: white wine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: beer
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: rose wine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: red wine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: alcoholic beverages (general)
Number of subjects: 21
Study: 16059624

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 12135019

Group type: EXPERIMENTAL
Intervention: Omeprazole with or without additional antibiotic therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (H. pylori negative patients)
Number of subjects: 75
Study: 9435323

Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Positive plasma CMV DNA PCR
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Each log10 increase in baseline CMV DNA load
Number of subjects: 619
Study: 8620666

Group type: EXPERIMENTAL
Intervention: Zileuton 600mg 4 times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zileuton + Prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisone 40mg
Number of subjects: 0
Study: 2909689

Group type: EXPERIMENTAL
Intervention: Acute surgery (AS: 0 to 3 days after the SAH)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Intermediate surgery (IS: 4 to 7 days after the SAH)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Late surgery (LS: 8 days to an indefinite time after the SAH)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 216

Group type: COMPARATOR
Intervention: No nimodipine (placebo + patients not entered into the nimodipine trial)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Late surgery with nimodipine
Number of subjects: 216
Study: 338101

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31944870

Group type: EXPERIMENTAL
Intervention: Accurate productions of real words (e.g., 'leaf')
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Misarticulated words (e.g., 'weaf' or 'yeaf')
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Common misarticulation condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Uncommon misarticulation condition
Number of subjects: 40
Study: 29778325

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 2325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2325
Study: 27710808

Group type: EXPERIMENTAL
Intervention: High-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 40 mg daily)
Number of subjects: 1641
Study: 24836698

Group type: COMPARATOR
Intervention: Conventional BT (CON)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Partially unloaded BT (PART)
Number of subjects: 32
Study: 22503015

Group type: EXPERIMENTAL
Intervention: Myofascial physical therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Global therapeutic massage
Number of subjects: 81
Study: 20085491

Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg twice daily) plus optimized background therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimized background therapy alone
Number of subjects: 0
Study: 18679601

Group type: EXPERIMENTAL
Intervention: Shengmai Injection (SMI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 90
Study: 15939026

Group type: EXPERIMENTAL
Intervention: TOE group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FOOT group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LEG group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Full-body display
Number of subjects: 24
Study: 12576953

Group type: EXPERIMENTAL
Intervention: Oronasal mask ventilation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nasal mask ventilation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both mask types
Number of subjects: 70
Study: 10543335

Group type: EXPERIMENTAL
Intervention: tolterodine 2 mg twice daily
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: oxybutynin 5 mg three times daily
Number of subjects: 277

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 277
Study: 8983874

Group type: EXPERIMENTAL
Intervention: Supine venous pump function test
Number of subjects: 70
Study: 1938567

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with four heat treatments
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with one heat treatment
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Radiotherapy alone
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control arm (untreated lesions)
Number of subjects: 1
Study: 7278083

Group type: EXPERIMENTAL
Intervention: Cimetidine 10 mg intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine high dose (not specified)
Number of subjects: 0
Study: 31476911

Group type: EXPERIMENTAL
Intervention: Genetically predicted systolic blood pressure (gSBP) increase by 10 mm Hg
Number of subjects: 5596
Study: 29499470

Group type: EXPERIMENTAL
Intervention: English as a Medium of Instruction (EMI) program
Number of subjects: 1288

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1288
Study: 27077973

Group type: EXPERIMENTAL
Intervention: STARFISH program for six weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 23
Study: 25295663

Group type: EXPERIMENTAL
Intervention: Oral hydrogen-rich tablets (2 g per day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral hydrogen-rich tablets (2 g per day) and topical hydrogen-rich packs (6 times per day for 20 minutes)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (traditional treatment protocol for soft tissue injury)
Number of subjects: 36
Study: 22439287

Group type: EXPERIMENTAL
Intervention: Blinded parent-proxy ratings of the COPM
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unblinded parent-proxy ratings of the COPM
Number of subjects: 50
Study: 19766645

Group type: EXPERIMENTAL
Intervention: PegIFNalpha2a plus RBV 800-1200 mg/day
Number of subjects: 431

Group type: COMPARATOR
Intervention: PegIFNalpha2b plus RBV 800-1200 mg/day
Number of subjects: 431
Study: 17655764

Group type: EXPERIMENTAL
Intervention: CTG + ST-analysis of the fetal ECG
Number of subjects: 5100

Group type: COMPARATOR
Intervention: CTG + FBS
Number of subjects: 5100
Study: 16052058

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (INF-gamma) in AA patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (INF-gamma) in extensive form AA (II group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (INF-gamma) in localized form AA (I group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (INF-gamma) in family history AA (III group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (INF-gamma) between extensive and localized forms of AA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) in AA patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) in extensive form AA (II group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) in localized form AA (I group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) in family history AA (III group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) between extensive and localized forms of AA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) between extensive form and family history AA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) between localized form and family history AA
Number of subjects: 30
Study: 12131705

Group type: EXPERIMENTAL
Intervention: Normal activity
Number of subjects: 281

Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 281
Study: 12237656

Group type: EXPERIMENTAL
Intervention: Gestational hypertension
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (normotensive subjects)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 58
Study: 9422572

Group type: EXPERIMENTAL
Intervention: 3.5 Gy daily fractions
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: bio-average and bio-maximum dose (corrected for fraction size)
Number of subjects: 57

Group type: COMPARATOR
Intervention: uncorrected dose distributions
Number of subjects: 57
Study: 8024137

Group type: EXPERIMENTAL
Intervention: Head immobilization (passive immobilization with the head held flat against a rigid board)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No stabilization
Number of subjects: 31
Study: 2637357

Group type: EXPERIMENTAL
Intervention: Toothbrushing-instruction (individual training in horizontal scrubbing)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Incentive (promise of a special prize for brushing well)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No-instruction group
Number of subjects: 64

Group type: COMPARATOR
Intervention: No-incentive condition
Number of subjects: 64
Study: 871980

Group type: EXPERIMENTAL
Intervention: 500 rads of cobalt‐60 gamma irradiation a few hours before excision of the lesion
Number of subjects: 125

Group type: COMPARATOR
Intervention: No irradiation (control group)
Number of subjects: 125
Study: 31356373

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control as usual (CAU)
Number of subjects: 200
Study: 28328347

Group type: EXPERIMENTAL
Intervention: CSL830 40 IU/kg twice weekly
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CSL830 60 IU/kg twice weekly
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 25833063

Group type: EXPERIMENTAL
Intervention: White wine (4 ml/kg body weight, 0.48 g/kg of alcohol 12%, corresponding to 2-3 glasses/daily) and extra-virgin olive oil (treatment A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Extra-virgin olive oil alone (treatment B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: White wine and extra-virgin olive oil (treatment A)
Number of subjects: 20
Study: 23517291

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 10 mg/day
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 673

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 10 mg/day and 50 mg/day
Number of subjects: 673
Study: 22586828

Group type: COMPARATOR
Intervention: Heel lift of six mm or more under the right foot
Number of subjects: 30

Group type: COMPARATOR
Intervention: Heel lift of four mm or more under the left foot
Number of subjects: 30

Group type: COMPARATOR
Intervention: Heel lift of eight mm or more under the right foot
Number of subjects: 30

Group type: COMPARATOR
Intervention: Heel lift of seven mm or more under the left foot
Number of subjects: 30
Study: 19524243

Group type: EXPERIMENTAL
Intervention: Exercise training (3-4 times per week for 6 months at 50% of maximal oxygen consumption)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 267
Study: 16621868

Group type: EXPERIMENTAL
Intervention: 10 mg/day ezetimibe (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mg/day ezetimibe as an add-on to 20 mg/day simvastatin (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dose escalation from 10 to 40 mg/day atorvastatin (Group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: De novo monotherapy with 40 mg/day atorvastatin (Group D)
Number of subjects: 60
Study: 23570208

Group type: EXPERIMENTAL
Intervention: Health Buddy (interactive device for asthma self-management)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Asthma diary (control group)
Number of subjects: 134
Study: 11371418

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Splint (MAS)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control oral plate (A)
Number of subjects: 28
Study: 9296410

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 0, 25, 50, or 75 microg x kg(‐1) x min(‐1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 50-75 microg x kg(‐1) x min(‐1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Propofol infusion of 25-50 microg x kg(‐1) x min(‐1) in combination with alfentanil infusion of 0.2-0.4 microg x kg(‐1) x min(‐1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Deep sedation with propofol
Number of subjects: 72
Study: 8289986

Group type: EXPERIMENTAL
Intervention: 2 g elemental calcium per day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2825369

Group type: EXPERIMENTAL
Intervention: Combined hyperthermia/radiotherapy
Number of subjects: 158

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 158

Group type: COMPARATOR
Intervention: Planned postoperative radiation without hyperthermia
Number of subjects: 158

Group type: COMPARATOR
Intervention: Radiotherapy alone in cases of inoperability
Number of subjects: 158
Study: 31714430

Group type: EXPERIMENTAL
Intervention: IL-32γ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-32α
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-32β
Number of subjects: 0

Group type: COMPARATOR
Intervention: IL-32α and IL-32β
Number of subjects: 0
Study: 30137657

Group type: EXPERIMENTAL
Intervention: Information-based website (IG)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 337
Study: 26111989

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT) with quadriceps strengthening exercise (QSE)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Quadriceps strengthening exercise (QSE) alone
Number of subjects: 39
Study: 24507630

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) for PTSD (n = 30)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual treatment (n = 29)
Number of subjects: 59
Study: 22293542

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Number of subjects: 255

Group type: COMPARATOR
Intervention: atazanavir
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: both arms
Number of subjects: 255
Study: 20854144

Group type: EXPERIMENTAL
Intervention: etravirine 200 mg twice-daily
Number of subjects: 600

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 600